Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hetlioz
Pharma
Cycle's 2nd hostile takeover bid in 5 months rejected by Vanda
For the second time in five months, Vanda Pharmaceuticals has rejected an $8-per-share takeover bid from Cycle Pharmaceuticals of England.
Kevin Dunleavy
Oct 14, 2024 3:18pm
Vanda gets $466M takeout bid from Cycle Pharma
Jun 6, 2024 10:10am
Supreme Court rejects Vanda's Hetlioz patent revival appeal
Apr 22, 2024 3:49pm
15 years later, Vanda secures another FDA nod for Fanapt
Apr 3, 2024 11:04am
Vanda scores courtroom win over FDA in records case
Mar 29, 2023 3:15pm
Teva, Apotex prevail over Vanda in patent infringement case
Dec 14, 2022 2:11pm
